Overall, these analysts combined provide a consensus target of $45 according to MarketBeat.
From ATNM's valuation on Wednesday at 1:30PM EST, this provides the profile with potential upside over 425%.
Now, I'm not saying ATNM is going to go soaring to that level today, but you must take note of the potential upside these analysts are providing with their price targets.
#3 Potential ATNM Catalyst
In the past 6 months, ATNM has shown the ability to make major short-term bursts.
In fact, on multiple occasions, ATNM has made multi-dollar moves in the blink of an eye.
Here are a handful of examples:
#1. On 10/2/20, ATNM jumped $3.30+ from a low of $9.00 to a high of $12.36 high on 10/19/20.
#2. On 11/2/20, ATNM popped $3.40+ from a low of $9.71 to a high of $13.18 high on 11/17/20.
#3. On 1/28/21, ATNM climbed $2.50+ from a low of $7.51 to a high of $10.15 high on 2/9/21.
#4. On 3/5/21, ATNM surged $2.40+ from a low of $7.05 to a high of $9.48 high on 3/15/20.
As you can see, all of these moves happened in roughly 2 weeks or less.
Could ATNM's next big breakout be right around the corner?
#4 Potential ATNM Catalyst
Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC
- Positive preclinical data support continued development with strong potential in bone marrow transplant, adoptive cell therapy and gene therapy applications
- Potent alpha emitter Actinium-225 targeted to CD45 cells demonstrates positive biodistribution profile and dose-dependent conditioning capabilities
NEW YORK, March 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that preclinical feasibility data supporting an Actinium-225-based CD45-targeted Next-Generation conditioning agent has been accepted for poster presentation at the American Association of Cancer Research (AACR 2021) annual meeting being held virtually April 10th – 15th, 2021. The data to be presented includes initial dose escalation, safety, tolerability, and conditioning experiments of an Ac-225-based CD45 ARC or antibody radiation conjugate. Dosimetry results with this Ac-225-based alpha emitting ARC showed selective accumulation in immune cell target organs such as bone marrow, spleen, and liver with the potential for lower exposure to non-target tissues from longer path length beta emitter radioisotopes like Iodine-131 and Lutetium-177. The data to be presented demonstrate that conditioning with this Ac-225-based CD45-targeting agent result in depletion of peripheral immune cells and hematopoietic progenitor cells, thereby enabling engraftment of donor cells. A dose dependent response was observed with low doses depleting white blood without effecting hematopoietic progenitor cells, representing a lymphodepletive dose that is relevant for adoptive cell therapies such as CAR-T, while higher doses eliminated peripheral immune cells and hematopoietic progenitor cells, which is applicable to ex vivo gene therapies and BMT or bone marrow transplant.
This program further augments Actinium's targeted conditioning portfolio that is led by Iomab-B, an ARC consisting or the radioisotope Iodine-131 and the CD45 targeting antibody apamistamab. In total, apamistamab has been studied in several hundred patients. Iomab-B is currently being studied in the pivotal Phase 3 SIERRA trial for BMT conditioning in patients with active relapsed or refractory acute myeloid leukemia age 55 and above that is expected to complete enrollment in 2021.
Dr. Dale Ludwig, Actinium's Chief Scientific and Technology Officer said, "We are excited to present this data supporting an Ac-225 antibody radiation-conjugate at AACR and to have the opportunity to develop potentially safer and better targeted chemotherapy-free conditioning agents. Recent cases of secondary malignancies potentially tied to toxic chemotherapy regimens highlight the urgent need for improved conditioning to enable the very promising cell and gene therapy strategies to treat diseases such as Sickle Cell Disease and Beta-Thalassemia. As advances in cell and gene therapies address more disease indications and thus a larger overall patient population, our commitment to developing targeted conditioning agents to improve patient access to the these potentially curative therapies and patient outcomes grows stronger. We look forward to further optimizing this construct to enable advancement into the clinic."
Read the full article here.
#5 Potential ATNM Catalyst
Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting
- TCT conference visibility bolsters strong momentum as SIERRA nears full enrollment following recent positive interim analysis
- Strong results from 75% of patient enrollment highlighted in CME events, oral presentations and investigator interactions at TCT
NEW YORK, Feb. 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its presence at the 2021 Transplantation & Cellular Therapy (TCT) Annual Meeting, which is being held virtually from February 8th – 12th. The TCT meeting organizes thousands of transplant professionals from over five hundred transplant centers worldwide and is a seminal event for Actinium given its focus on targeted conditioning for bone marrow transplant (BMT), CAR-T and other adoptive cell therapies and gene therapy. At TCT, Actinium's pivotal Phase 3 trial SIERRA trial for Iomab-B was featured in 2 oral presentations, as well as CME event focused on AML and BMT and in investigator interactions led by Actinium's clinical development and medical affairs teams.
Dr. Mark Berger, Actinium's Chief Medical Officer, said, "TCT is the ideal venue to showcase Actinium's Iomab-B and Iomab-ACT targeted conditioning programs given the concentrated audience of thought leaders in these fields that TCT brings together. The timing of TCT is also ideal as it follows shortly after ASH resulting in a data rich period for Actinium that drives investigator interest. This is particularly the case this year as we have built strong momentum in SIERRA following positive data from 75% enrollment featured in 2 oral presentations at ASH and now in 2 oral presentations at this year's TCT, which has driven high levels of investigator and referring physician interactions. We have coupled this with bolstered outreach efforts, which will continue beyond TCT, that have resulted in new site activation despite the advanced stage of SIERRA and robust enrollment rates that give us great confidence in completing SIERRA enrollment rapidly."
Read the full article here.
Coverage is officially initiated on ATNM. When you have a second later on, do this: